Despite a wave of M&A deals aimed at increasing efficiency and lowering expenses in the pharmaceutical industry, drug prices continue to rise, with several drug companies nearly doubling the costs of key products over the last 7 years. That's the conclusion of an analysis prepared for <em>Bloomberg</em> by DRX, a California-based provider of health software.
written on 01.05.2014
Report: Drug prices skyrocketing, with no end in sight
